Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer
Public ClinicalTrials.gov record NCT02500121. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blinded, Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer: Hoosier Cancer Research Network GU14-182
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multi-institutional, randomized, placebo controlled, double-blinded phase II trial of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer who have achieved at least stable disease on first-line chemotherapy.
Study identification
- NCT ID
- NCT02500121
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 108 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 11, 2015 (Actual)
- Primary completion
- Jul 1, 2019 (Actual)
- Completion
- Jan 1, 2021 (Actual)
- Last update posted
- Sep 30, 2022
2015 – 2021
United States locations
- U.S. sites
- 28
- U.S. states
- 20
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona at Dignity Health St. Joseph's | Phoenix | Arizona | 85004 | — |
| City of Hope Comprehensive Cancer Center | Duarte | California | 91010 | — |
| University of Southern California | Los Angeles | California | 90033 | — |
| Georgetown University | Washington D.C. | District of Columbia | 20057 | — |
| University of Florida | Gainesville | Florida | 32610 | — |
| IU Health Goshen Center for Cancer Care | Goshen | Indiana | 46526 | — |
| Indiana University Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| IU Health Central Indiana Cancer Center | Indianapolis | Indiana | 46219 | — |
| Community Regional Cancer Care | Indianapolis | Indiana | 46256 | — |
| Community Healthcare System | Munster | Indiana | 46321 | — |
| University of Maryland | Baltimore | Maryland | 21201 | — |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | Maryland | 21231 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Washington University: Siteman Cancer Center | St Louis | Missouri | 63110 | — |
| GU Cancer Research Network, LLC | Omaha | Nebraska | 68130 | — |
| The John Theuer Cancer Center at Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| University of New Mexico Cancer Center | Albuquerque | New Mexico | 87106 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Tisch Cancer Institute at Mount Sinai Medical Center | New York | New York | 10029 | — |
| University of Rochester Medical Center | Rochester | New York | 14642 | — |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27514 | — |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37232 | — |
| Huntsman Cancer Institute University of Utah | Salt Lake City | Utah | 84112 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02500121, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 30, 2022 · Synced Nov 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02500121 live on ClinicalTrials.gov.